Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension

This 6-month, double-blind,extension study will provide further information regarding the
long-term safety and tolerability of intepirdine (RVT-101) in subjects with DLB who have
participated in the double-blind, placebo-controlled, lead-in study RVT-101-2001. The study
duration for subjects in study centers in the USA will be 12 months.

Subjects who were randomized to the RVT-101 35-mg and RVT-101 70-mg treatment groups in
lead-in study RVT-101-2001 will remain in the same treatment groups for this study; subjects
who were randomized to the placebo treatment group in the lead-in study will be assigned to
the RVT-101 70-mg treatment group in this study.

Various background therapies, including acetylcholinesterase inhibitors and memantine, will
be allowed.

Inclusion Criteria:

- Participated in the lead-in study RVT-101-2001.

Exclusion Criteria:

- Any clinically relevant concomitant disease, which, in the opinion of the
Investigator, makes the subject unsuitable for inclusion in the study.